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Abstract
Background: Parkinson's disease (PD) is the most common movement disorder. Extrapyramidal
motor symptoms stem from the degeneration of the dopaminergic pathways in patient brain.
Current treatments for PD are symptomatic, alleviating disease symptoms without reversing or
retarding disease progression. Although the cause of PD remains unknown, several pathogenic
factors have been identified, which cause dopaminergic neuron (DN) death in the substantia nigra
(SN). These include oxidative stress, mitochondrial dysfunction, inflammation and excitotoxicity.
Manipulation of these factors may allow the development of disease-modifying treatment strategies
to slow neuronal death. Inhibition of DJ-1A, the Drosophila homologue of the familial PD gene DJ-
1, leads to oxidative stress, mitochondrial dysfunction, and DN loss, making fly DJ-1A model an
excellent in vivo system to test for compounds with therapeutic potential.
Results:  In the present study, a Drosophila  DJ-1A model of PD was used to test potential
neuroprotective drugs. The drugs applied are the Chinese herb celastrol, the antibiotic
minocycline, the bioenergetic amine coenzyme Q10 (coQ10), and the glutamate antagonist 2,3-
dihydroxy-6-nitro-7-sulphamoylbenzo[f]-quinoxaline (NBQX). All of these drugs target pathogenic
processes implicated in PD, thus constitute mechanism-based treatment strategies. We show that
celastrol and minocycline, both having antioxidant and anti-inflammatory properties, confer potent
dopaminergic neuroprotection in Drosophila DJ-1A model, while coQ10 shows no protective effect.
NBQX exerts differential effects on cell survival and brain dopamine content: it protects against
DN loss but fails to restore brain dopamine level.
Conclusion: The present study further validates Drosophila as a valuable model for preclinical
testing of drugs with therapeutic potential for neurodegenerative diseases. The lower cost and
amenability to high throughput testing make Drosophila  PD models effective in vivo tools for
screening novel therapeutic compounds. If our findings can be further validated in mammalian PD
models, they would implicate drugs combining antioxidant and anti-inflammatory properties as
strong therapeutic candidates for mechanism-based PD treatment.
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Background
PD is the second most common neurodegenerative dis-
ease in the western world and the single most common
movement disorder. Over 1 million people in the United
States are affected [1]. Symptoms including rigidity, rest-
ing tremor, bradykinesia and postural instability are due
to degeneration of the brain's nigrostriatal system with
progressive loss of DNs in the substantia nigra pars com-
pacta (SNpc), accompanied by depletion of the transmit-
ter dopamine in the striatum. Current pharmacological
therapy for PD ameliorates symptoms for a limited period
of time, without retarding or reversing disease progres-
sion. Currently administered drugs work by increasing the
concentration of functional dopamine in the striatum by
one of a number of mechanisms: replacing dopamine
itself (L-Dopa), inhibiting dopamine-degrading enzymes
to prolong its half-life (Entacapone, Selegeline), or mim-
icking the effect of dopamine on its receptors with
dopamine agonists (Bromocriptine, Pergolide, Pramipex-
ole, etc). L-Dopa has remained the single most effective
PD drug since its introduction decades ago [2,3].
New treatment strategy aimed at slowing or halting DN
death is desired. In the course of elucidating pathogenic
events that eventually lead to PD, at least four major
mechanisms have been identified: oxidative stress, pro-
tein aggregation, inflammation and excitotoxicity [4,5]. It
is assumed that these pathways constitute a complex net-
work of events that eventually leads to DN death. Conse-
quently, effective disease-modifying therapy would
require addressing a combination of neurodegenerative
mechanisms within the SN.
Even though the vast majority of PD cases are sporadic idi-
opathic forms, recent identification of a number of genes
(PARK 1-11) responsible for rare familial cases has pro-
vided tremendous insight into the pathogenesis of the dis-
ease. The rationale behind studying rare genetic forms of
a common sporadic disease is the assumption that they
share key biochemical pathways. Of the ten genetic loci
linked to familial PD, six gene products have been charac-
terized so far: α-Synuclein, Parkin, UCH-L1, DJ-1, PINK1,
and LRRK2 [5,6]. DJ-1 is a relatively small, evolutionarily
conserved protein belonging to the ThiJ/PfpI/DJ-1 family.
Members of the ThiJ/PfpI/DJ-1 family include chaper-
ones, proteases and transcriptional regulators [7], yet DJ-
1's biochemical function relevant to PD remains to be
defined. DJ-1 has been implicated in diverse cellular proc-
esses, including cellular transformation and tumorigene-
sis [8,9], transcriptional regulation and RNA binding [10],
androgen receptor signaling [11,12], spermatogenesis
[13], and oxidative stress response [14,15]. In vitro studies
showed that DJ-1 responds to oxidative stress induced by
paraquat exposure, with a shift of its iso-electric point
towards a more acidic form (from pI 6.2 to pI 5.8) [15].
Postmortem analysis of PD brains detected higher con-
centrations of the acidic DJ-1 isoforms, as compared to
healthy controls [7]. DJ-1 is a hydrogen peroxide (H2O2)-
responsive protein. H2O2 exposure oxidizes all its cysteine
residues (Cys 46, 53, 106) to cysteine sulfonic acid [16],
with Cys 106 being most sensitive. These studies demon-
strate a direct modification of DJ-1 protein by reactive
oxygen species (ROS), nourishing the notion that DJ-1
might act as a free radical scavenger or sensor. Cell culture
studies of DJ-1 deficient neuronal cells revealed increased
susceptibility to H2O2, MPP+, 6-hydroxydopamine, and
rotenone [12,17,18], whereas DJ-1 overexpression dra-
matically reduced H2O2-induced neuronal death [17,18].
Oxidative stress results in mitochondrial relocalization of
DJ-1, which is mediated by oxidation of Cys 106 [19].
Consistent with DJ-1 playing an important role in oxida-
tive stress response, genetic studies in Drosophila and mice
showed accumulation of ROS and increased sensitivity to
oxidative stimuli, including H2O2  and MPTP, in DJ-1
mutants [18,20,22].
Minocycline is a member of the tetracycline group of anti-
biotics. Minocycline has been found to have additional
anti-inflammatory and antioxidant properties independ-
ent of its antibacterial activity [23,26], which may be use-
ful for the treatment of neurodegenerative diseases
including PD. Minocycline has also been shown to have
neuroprotective effects in animal models of other patho-
logical conditions, including ischemia and stroke, trau-
matic brain injury, amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS), Huntington's disease (HD), and
the MPTP model of PD in mouse [27,30]. Potency appears
to arise from the modulation of inflammatory cytokine
release, microglia activation, nitric oxide production,
matrix metalloprotease activation, and apoptotic cell
death. Minocycline has an oral bioavailability of almost
100% and its absorption, unlike other tetracyclines, is not
reduced by ingestion with food [31]. High lipophilicity
allows its easy diffusion into brain tissues. Minocycline
also has a lower urinary excretion than other tetracyclines
and is thus safer in elderly patients with impaired renal
function [32].
Celastrol is a triterpene extracted from the root bark of an
ivy-like, creeping plant called Triperygium wilfordii (TW)
that is indigenous to Southern China. Extracts of the plant
have had a long history of use in traditional Chinese med-
icine for treating fever, chills, edema and joint pain, con-
ditions commonly associated with inflammation [33].
Celastrol was found to suppress microglial cell activation,
release of the inflammatory cytokines TNF-α and IL-1β by
human macrophages and monocytes, and the production
of nitric oxide (NO) by iNOS [33]. Furthermore, celastrol
was demonstrated to be a potent inhibitor of induced
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over 15-fold more antioxidant potency than α-tocopherol
[34]. Celastrol protected both the outer and inner mito-
chondrial membrane from peroxidation, possibly medi-
ated by its radical-scavenging dienonephenol moiety,
while the anionic carboxyl group protects the inner mem-
brane from radical attacks by stabilizing its negative sur-
face charge. In a rat model of Alzheimer's disease (AD),
celastrol improved memory and learning in psychomo-
tor-activity tests (PMA) [33]. Low nanomolar concentra-
tions of the drug showed efficacy in all the studies
mentioned above.
CoQ10 (also known as ubiquinone) is composed of a
quinone ring and a 10-isoprene unit tail. It is an obliga-
tory cofactor in the mitochondrial respiratory chain. As a
bioenergetic agent, it serves as an electron acceptor in
complexes I and II/III of the electron transport chain.
Mitochondrial dysfunction has been frequently observed
in PD, and several lines of evidence support its causative
role in disease pathogenesis. For example, a 30% to 40%
reduction in complex I activity was observed in sporadic
PD, and MPTP induces parkinsonism by inhibiting com-
plex I activity [35]. CoQ10 is also a potent antioxidant dis-
tributed in all membranes throughout the cell. It is able to
work in concert with α-tocopherol and participates in the
recovery of cells from oxidative stress [36,37]. Levels of
coQ10 measured in mitochondria from PD patients were
significantly lower than in age-matched controls [38],
while at the same time the percentage of oxidized coQ10
was relatively increased [39]. In in vitro models, coQ10
could protect against MPP+ and rotenone induced toxicity
[40,42]. In animal models of ALS and HD, coQ10 treat-
ment also showed beneficial effects [43,44]. In the MPTP
mouse model of PD, oral treatment of young mice with
coQ10 and nicotiamide attenuated the effect of low dose
MPTP administration, while coQ10 alone attenuated
dopamine depletion in the striatum [45]. CoQ10 treat-
ment (200 mg/kg/day) in aged (1 year old) MPTP-treated
mice, whose nervous system might already exhibit degen-
erative changes, showed that it significantly attenuated
MPTP-induced loss of striatal dopamine and loss of TH-
immunoreactive fibers in the striatum [46]. CoQ10
administration can increase mitochondrial content of
coQ10 in the cortex of 1-year-old rats [43]. Similar prom-
ising results have subsequently been generated using a
monkey MPTP model of PD [47]. CoQ10 is extremely
lipophilic, making it easy to cross the BBB. Its absorption
is improved by the inclusion of lipid in the formulation
and by taking it with food.
NBQX (2,3-dihydroxy-6-nitro-7-sulphamoylbenzo[f]-
quinoxaline) is a potent competitive AMPA-receptor
antagonist, belonging to the quinoxalinediones group
[48]. AMPA-selective glutamate receptor antagonists con-
stitute potential neuroprotective agents by counteracting
the excitotoxic effects of excess glutamate. In the MPP+
mouse model of PD, AMPA receptor antagonists were
shown to have greater therapeutic potential than NMDA
receptor antagonists [49]. The quinoxalindione deriva-
tives were discovered in 1988 and are still undergoing
intensive study [50]. NBQX exhibits improved AMPA
receptor selectivity compared to earlier quinoxalindiones
[51]. It has systemic activity and was first shown to have
therapeutic effects by protecting against cerebral ischemia
after carotid artery occlusion in mice [51]. NBQX has thus
been used as the antagonist of choice in many "in vivo"
and "in vitro" models. Besides its anti-stroke properties,
NBQX also showed efficacy against PD [52], demyelinat-
ing disorders [53], and trauma [54].
Given that celastrol, minocycline, coQ10, and NBQX have
different mechanisms of action and all shown efficacy in
various neurological disease models, we decided to test
their efficacy in a Drosophila DJ-1 model of PD. There are
two DJ-1 homologues in Drosophila, DJ-1A and DJ-1B.
Despite the fact that DJ-1A is more closely related to
human DJ-1 at the sequence level, DJ-1B has been the
main focus of research simply because of its ubiquitous
and higher level of expression. It should be pointed out
that DJ-1A, despite its low level of expression, is expressed
in adult brain and is inducible under certain conditions
[22]. Results on DJ-1B function in stress response and DN
survival using various genetic mutants have been diver-
gent [21,22,55]. Studies on DJ-1A function in stress
response and DN survival using two different DJ-1A RNAi
lines by independent groups have been consistent
[20,56], although one study reported that a genomic dele-
tion mutant of DJ-1A, in which the entire DJ-1A locus and
some surrounding sequence were deleted, showed stress
sensitivity but no DN loss [21]. The lack of DN loss phe-
notype in the DJ-1A genomic deletion mutant could be
caused by a genome-wide compensatory response to the
deletion of DJ-1A; alternatively, the phenotypes induced
by tissue-specific DJ-1A RNAi may require some non cell-
autonomous function of DJ-1A. The efficiency of the DJ-
1A RNAi transgene used in this study and evidence that
the DJ-1A RNAi phenotype is unlikely due to "off target"
effects have been presented in previous studies [20].
Given that the DJ-1A RNAi model recapitulates two fea-
tures of PD: loss of DN and reduction of brain dopamine
levels [20,56], we decided to test the drugs on this model.
We expect that results from this study will help under-
stand the role of DJ-1 dysfunction in PD pathogenesis and
validate the usefulness of fly PD models in pharmacolog-
ical studies.
Results
To evaluate the effects of potential neuroprotective drugs
in vivo, DN survival and dopamine content of the brain
were measured in a fly DJ-1A RNAi model of PD [20]. TheBMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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effects of the drugs celastrol, minocycline, NBQX, and
coQ10 on DJ-1A RNAi-induced dopaminergic dysfunc-
tion and degeneration were investigated. One pathologi-
cal hallmark of PD is a progressive loss of DNs in the SN.
It has been shown that DNs in a circumscribed brain
region, the dorsomedial cluster (DMC), degenerate in
Drosophila models of PD [57,58]. Thus, serial frontal sec-
tions across the brains of aged flies were first immunos-
tained using the anti-tyrosine hydroxylase (TH) antibody
that specifically detects dopamine-synthesizing neurons.
Immunopositive neurons of the DMC were detected with
the peroxidase/DAB staining methods and quantified.
Although the validity of the paraffin section peroxidase/
DAB staining method originally used to detect DN loss in
the fly α-Syn model was questioned [57,59,62], later stud-
ies using confocal analysis of whole-mount TH immunos-
taining confirmed α-Syn toxicity in fly DNs [63]. These
results suggest that both the paraffin section peroxidase
staining and whole-mount immunostaining methods are
valid for detecting TH+ neurons. Consistently, we could
observe the DN loss phenotype in DJ-1A RNAi flies using
either the whole-mount confocal microscopy (Fig. 1), or
the paraffin section peroxidase staining method [20]. In
DJ-1A RNAi flies, the age-dependent loss of DNs was
shown to be preceded and accompanied by a decrease of
dopamine levels in the brain [20]. Therefore, in the sec-
ond set of experiments we studied whether the drugs
would also affect levels of brain dopamine, as measured
by HPLC analysis of fly head homogenates.
Age-dependent loss of DNs and reduction of brain 
dopamine level in Ddc-Gal4>DJ-1A RNAi flies
An age-dependent loss of DNs in the DJ-1A RNAi flies was
observed in two independent studies where the dopamin-
ergic specific transcriptional regulator TH-GAL4 or dopa
decarboxylase (Ddc)-Gal4 were used to direct the expres-
sion of two different DJ-1A RNAi transgenes [20,56].
Since the culture conditions used in those previous stud-
ies were different from the current study, in which animals
were fed with yeast paste or drug-containing yeast paste,
Ddc-Gal4>DJ-1A RNAi flies cultured under yeast paste
condition were first analyzed for DN number and brain
dopamine content. Young, 1-day-old Ddc-Gal4>DJ-1A
RNAi  flies and age-matched Ddc-Gal4/+  control flies
showed no significant difference in their number of TH-
positive (TH+) neurons within the DMC (22.6 ± 1.98 in
DJ-1A RNAi flies vs. 21.20 ± 1.97 in controls, P = 0.98)
(Fig. 2). With age, both DJ-1A RNAi flies and control flies
showed a reduction of TH+ neurons (Fig. 2). The age-
dependent loss of TH+ neurons was more substantial
when DJ-1A was deficient: DJ-1A RNAi flies aged for 25
days suffered a 55.3% decrease of TH+ neurons within the
DMC, as compared to 1-day-old flies of the same geno-
type (22.6 ± 1.98 at 1 day vs. 10.1 ± 1.31 at 25 days),
whereas 25-day-old control flies only exhibited a 24.3%
loss compared to 1-day-old flies of the same genotype
(21.2 ± 1.97 at 1 day vs. 16.1 ± 1.95 at 25 days). Thus, at
25 days of age, the number of TH+ neurons within the
DMC of Ddc-Gal4>DJ-1A RNAi flies was 62.8% of age-
matched Ddc-Gal4/+ controls (P < 0.0001 in ANOVA with
Dunnett's post test). Another independent transgenic fly
line for the same UAS-DJ-1A RNAi transgene showed sim-
ilar degree of TH+ neuron loss when driven by Ddc-Gal4
driver (data not shown). Consistent with the DJ-1A RNAi
effect being caused by inhibition of DJ-1A function
instead of some "off-target" effect, co-expression of
human DJ-1 (hDJ-1) was able to rescue DJ-1A RNAi-
induced loss of TH+ neurons (Fig. 2). In previous studies,
control flies (TH-Gal4/+) aged at 35 days did not show
obvious DN number change [20]. The difference between
the control flies used in previous studies and the current
study is most likely due to the different feeding conditions
(yeast paste vs. standard fly food), since the TH-Gal4/+
control flies used in the previous study also showed a
decrease of TH+ neurons at 25 days of age when grown in
yeast-fed condition (data not shown).
We also measured brain dopamine contents in Ddc-
Gal4>DJ-1A RNAi and Ddc-Gal4/+ control flies fed with
yeast paste, using HPLC analysis of fly head extracts. Brain
dopamine levels in adult flies show dramatic age-depend-
ent reduction [20], such that at 25 days of age, a large
number of fly heads would be required to ensure quanti-
tative and reliable measurement of brain dopamine levels.
We therefore measured younger flies when dopamine
level can be reliably measured. Even when assayed at 10
days of age, Ddc-Gal4>DJ-1A RNAi flies already showed
more than 50% reduction of brain dopamine level com-
pared to Ddc-Gal4/+ control flies (Fig. 4). At this age, no
Whole-mount confocal immunofluorescence analysis of TH+  neurons in the DMC of Ddc-Gal4>DJ-1A RNAi flies Figure 1
Whole-mount confocal immunofluorescence analysis 
of TH+ neurons in the DMC of Ddc-Gal4>DJ-1A RNAi 
flies. Whole-mount brain samples of 25-day old Ddc-
Gal4>UAS-DJ-1A RNAi (A) or control Ddc-Gal4>UAS-GFP (B) 
flies were immunostained with anti-TH antibody and TH-
positive immunofluorescence signals were detected by con-
focal microscopy. Representative confocal images of the TH+ 
neurons in the DMC are shown. Asterisks mark the identifia-
ble TH+ neurons. Note that not only was there a reduction 
of TH+ neurons in Ddc-Gal4>UAS-DJ-1A RNAi flies compared 
to the control, the intensity of TH immunoreactivity was also 
reduced in the remaining neurons.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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Immunohistochemical analysis showing age-dependent loss of TH+ neurons in the DMC of Ddc-Gal4>DJ-1A RNAi flies Figure 2
Immunohistochemical analysis showing age-dependent loss of TH+ neurons in the DMC of Ddc-Gal4>DJ-1A 
RNAi flies. A-D: Frontal paraffin sections of adult fly brain were reacted with anti-TH antibody and detected with the peroxi-
dase/DAB staining method. Representative sections containing DA neurons in the DMC were shown for each genotype. A, B: 
Ddc-Gal4>DJ-1A RNAi flies; C, D: Ddc-Gal4/+ flies. A, C: TH-immunostaining of 1-day-old flies; B, D: TH-immunostaining of 25-
day-old flies. E: Statistical analysis of the number of DNs within the DMC of Ddc-Gal4/+, Ddc-Gal4>DJ-1A RNAi, and Ddc-
Gal4>DJ-1A RNAi+hDJ-1 genotyped flies. Flies were fed with wet yeast paste. Between 8-25 fly heads for each genotype and age 
were evaluated. Columns depict mean with standard deviation of the mean (SD). ***: P < 0.0001 in ANOVA with Dunnett's 
post test.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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obvious change in DN number was observed (data not
shown), suggesting that brain dopamine level change
occurred before DN loss instead of being caused by that.
These results showed that DJ-1A RNAi-induced DN
degeneration and reduction of brain dopamine content
can be observed under both standard feeding conditions
previously reported [20] and yeast feeding condition
reported here.
The effects of celastrol on DN number and brain dopamine 
content
We next tested the effects of drug candidates in modulat-
ing DJ-1A RNAi-induced dopaminergic phenotypes. We
found that celastrol treatment both prevented DN loss
and protected against dopamine depletion observed in
Ddc-Gal4>DJ-1A RNAi flies. The effects of celastrol treat-
ments are shown in Fig. 3 and Fig. 4. Immunostaining of
TH+ neurons in the DMC of Ddc-Gal4>DJ-1A RNAi flies
treated with celastrol at 5 μg/ml revealed a significant
increase in the number of these neurons (10.1 ± 1.3 in
untreated flies vs. 14.3 ± 1.0 in treated flies, a mean
increase of 41%, P < 0.01). When treated with a higher
dose of celastrol (20 μg/ml), a mean increase of 48% was
observed. As a control, we found that Ddc-Gal4>DJ-1A
RNAi+hDJ-1 flies with or without celastrol treatment had
similar number of TH+ neurons (Fig. 3B).
To further ascertain the neuroprotective effects of celas-
trol, brain dopamine levels were measured in 10-day-old
flies treated with celastrol. Our initial dosing experiments
showed that lower doses of celastrol were sufficient to pre-
serve brain dopamine level. Therefore we used two differ-
ent doses in the lower range, 1 μg/ml and 5 μg/ml, in
brain dopamine measurement experiments (Fig. 4). After
feeding with 1 μg/ml celastrol, mean dopamine levels in
Ddc-Gal4>DJ-1A RNAi flies were increased by 30% (9.7 ±
1.5 ng/ml in treated vs. 7.5 ± 2.1 ng/ml in untreated ani-
mals). However, this increase showed no statistical signif-
icance (P > 0.05). Treatment of flies with a higher dose of
celastrol (5 μg/ml) significantly increased dopamine lev-
els to 14.4 ± 3.4 ng/ml, a 92% increase (P < 0.01). Treat-
ment of Ddc-Gal4>DJ-1A RNAi flies with 1 μg/ml or 5 μg/
ml celastrol therefore preserved dopamine content at 58%
or 86% of wild type level, respectively.
The protective effects of celastrol appeared to be selective
to the Ddc-Gal4>DJ-1A RNAi flies, since celastrol treat-
ment in control Ddc-Gal4/+ flies did not produce any sig-
nificant changes in either TH+ neuron number or brain
dopamine level. TH+ neuron numbers in Ddc-Gal4/+ flies
were 17.1 ± 1.0 in 5 μg/ml celastrol-fed vs. 16.1 ± 2.0 in
yeast-fed only conditions (P > 0.05), and 16.4 ± 1.4 in 20
μg/ml celastrol-fed vs. 16.1 ± 2.0 in yeast-fed only condi-
tions (P > 0.05). Brain dopamine levels in Ddc-Gal4/+flies
were 18.8 ± 2.4 ng/ml in 1 μg/ml celastrol-fed and 16.7 ±
2.1 ng/ml in 5 μg/ml celastrol-fed conditions, compared
to 16.7 ± 5.0 ng/ml in yeast-fed only condition. These
changes were not statistically significant (P > 0.05 in both
comparisons).
The effect of minocycline on DN number and brain 
dopamine content
Treatment of Ddc-Gal4>DJ-1A RNAi flies with minocy-
cline also resulted in attenuation of both DN loss and
dopamine depletion in the brain (Fig. 3 and Fig. 4). DJ-1A
RNAi flies that received daily feeds of minocycline-con-
taining yeast paste (50 mg/ml) for 25 days showed a sig-
nificant increase of TH+ neurons within the DMC
compared to flies of the same genotype fed with yeast only
(Fig. 3). The mean number of TH+ neurons in the DMC of
minocycline (50 mg/ml) treated DJ-1A RNAi flies was
16.8 ± 2.0 (mean ± SD), as compared to 10.1 ± 1.3 in DJ-
1A RNAi flies fed with yeast only. Thus, treatment with 50
mg/ml minocycline resulted in a recovery of TH+ DMC
neurons in Ddc-Gal4>DJ-1A RNAi flies to wild type levels
(16.1 ± 2.0 at 25 days), which represented a 67% increase
compared to the same genotyped flies without drug treat-
ment.
We further examine the effects of minocycline on
dopamine concentrations in head homogenates of 10-
day-old Ddc-Gal4>DJ-1A RNAi flies. Daily oral uptake of
minocycline attenuated dopamine depletion in a dose-
dependent manner (Fig. 4). Ddc-Gal4>DJ-1A RNAi flies
treated with 25 mg/ml or 50 mg/ml minocycline showed
mean dopamine concentrations of 12.4 ± 2.3 ng/ml (P <
0.01) or 14.1 ± 3.7 ng/ml (P < 0.01), respectively, while
the same genotyped flies fed with yeast only had
dopamine level of 7.5 ± 2.1 ng/ml. Age-matched Ddc-
Gal4/+  control flies under yeast-fed condition had
dopamine levels at 16.7 ± 5.0 ng/ml. Hence, as compared
to the yeast-fed only condition, high dose minocycline
almost doubled dopamine levels in Ddc-Gal4>DJ-1A
RNAi flies, reaching 85% of wild type levels. Feeding with
lower dose minocycline (25 mg/ml) also increased
dopamine levels, although to a lesser extent, reaching
71% of wild type levels.
Minocycline had no effect on control Ddc-Gal4/+ flies,
when fed in high doses (50 mg/ml). Neither TH+ neuron
number (17.0 ± 1.0 in minocycline-fed condition vs. 16.1
± 2.0 in yeast-fed condition, P > 0.05), nor mean brain
dopamine level (16.7 ± 3.1 ng/ml in minocycline-fed con-
dition vs. 16.7 ± 5.0 ng/ml in yeast-fed condition, P >
0.05) was significantly different for Ddc-Gal4/+flies with
or without minocycline treatment. In lower dose minocy-
cline-feeding condition (25 mg/ml), however, a modest
reduction of dopamine level was observed in Ddc-Gal4/
+control flies (11.7 ± 1.5 ng/ml in minocycline-feeding
condition vs. 16.7 ± 5.0 ng/ml in yeast-feeding condition,
P  < 0.05), although no significant difference in DN
number was observed (data not shown). The significanceBMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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of this lower-dose minocycline effect on dopamine level is
not clear.
The effects of NBQX on DN number and brain dopamine 
content
The effect of NBQX treatment on DN number or brain
dopamine content was also analyzed. The number of TH+
neurons in the DMC of Ddc-Gal4>DJ-1A RNAi flies treated
with NBQX (30 mg/ml) was on average 76% higher than
age-matched untreated flies of the same genotype (17.7 ±
1.2 in NBQX-fed vs. 10.1 ± 1.3 in yeast-fed conditions, P
< 0.01). Thus NBQX treatment was sufficient to fully
restore DN number to wild type levels at 25 days of age
(Fig. 3 and Fig. 6E).
Surprisingly, NBQX-induced DN increase measured by
immunohistochemistry was not accompanied by restora-
tion of brain dopamine level assayed by neurochemistry
analysis (Fig. 5A). HPLC measurement of brain dopamine
concentration showed only a slight increase in Ddc-
Gal4>DJ-1A RNAi flies treated with NBQX (10.6 ± 3.1 ng/
ml in treated animals vs. 9.6 ± 3.4 ng/ml in untreated ani-
mals). Thus, in contrast to minocycline and celastrol,
NBQX attenuated TH+ neuron loss but failed to prevent
dopamine depletion in Ddc-Gal4>DJ-1A RNAi flies. Fur-
thermore, in contrast to the effect in Ddc-Gal4>DJ-1A
RNAi flies, NBQX treatment significantly reduced brain
dopamine level in control Ddc-Gal4/+ flies (Fig. 5, 13.1 ±
2.9 ng/ml in untreated vs. 8.7 ± 1.1 ng/ml in treated ani-
Statistical analysis of the effects of the various drugs on DN number in Ddc-Gal4>DJ-1A RNAi flies Figure 3
Statistical analysis of the effects of the various drugs on DN number in Ddc-Gal4>DJ-1A RNAi flies. A: The num-
bers of DNs in the DMC of drug-treated 25-day-old Ddc-Gal4>DJ-1A RNAi flies was determined by TH-immunostaining of par-
affin brain sections. These were compared with untreated Ddc-Gal4>DJ-1A RNAi flies or control Ddc-Gal4/+ flies with or 
without drug treatment. Animals were raised at 25°C. B: The numbers of DNs in the DMC of 25-day-old Ddc-Gal4>DJ-1A RNAi 
and Ddc-Gal4>DJ-1A RNAi+hDJ-1 flies with or without celastrol treatment (20 μg/ml) were determined by whole-mount TH-
immunostaining. Animals were raised at 29°C. Note that at 29°C the DJ-1A RNAi effect is stronger than 25°C. Results are the 
mean ± SD of 8-25 sectioned heads for each genotype and drug treatment. **: P < 0.01 in ANOVA with Dunnett's post test.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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mals, a decrease of 33%; P < 0.05). In addition, a trend of
decrease (though statistically non-significant) of TH+
neuron number was observed in NBQX-fed Ddc-Gal4/+
control flies (16.1 ± 2.0 in untreated vs. 14.8 ± 1.2 in
treated animals, P > 0.05; Fig. 3 and Fig. 6H), suggesting
that at the concentration used (30 mg/ml), NBQX exerted
certain toxic effects on the Ddc-Gal4/+ control flies.
The effects of coQ10 on DN number and brain dopamine 
content
The effects of coQ10 (100 mg/ml) feeding on DN number
and dopamine levels in Ddc-Gal4>DJ-1A RNAi flies or
control  Ddc-Gal4/+  flies were next analyzed. Mean
number of TH+ neurons in the DMC of Ddc-Gal4>DJ-1A
RNAi flies treated with 100 mg/ml coQ10 was 9.5 ± 1.5,
compared with 10.1 ± 1.3 in the untreated condition (P >
0.05). Ddc-Gal4/+ control flies treated with 100 mg/ml
coQ10 contained 16.9 ± 2.0 TH+ neurons in the DMC,
compared with 16.1 ± 2.0 in the untreated condition (P >
0.05) (Fig. 3, Fig. 6F). As shown in Fig. 5B, mean brain
dopamine levels of Ddc-Gal4>DJ-1A RNAi flies were 12.1
± 1.9 ng/ml in 100 mg/ml coQ10-treated vs. 11.4 ± 3.1
ng/ml in the untreated conditions (P > 0.05). In Ddc-Gal4/
+ control flies, brain dopamine levels were 17.0 ± 3.8 ng/
ml in 100 mg/ml coQ10-treated vs. 16.2 ± 2.3 ng/ml in
the untreated condition (P > 0.05) (Fig. 5B). Thus, coQ10
treatments had no significant effect on DA neuron
number or dopamine levels in Ddc-Gal4>DJ-1A RNAi flies
or control Ddc-Gal4/+ flies.
The effects of celastrol on locomotor activity and 
oxidative stress response
Locomotor dysfunction is frequently observed in Dro-
sophila PD models [55,57,64,65]. We found that aged DJ-
1A RNAi flies also exhibited reduced climbing activity
when compared to control flies. Further, this defect in
climbing activity was rescued by co-expressing hDJ-1 (Fig.
7A). To test whether celastrol treatment may modify this
phenotype, we fed newly eclosed flies with drug-contain-
ing yeast-paste. After 20 days of drug treatment, their
climbing activity was assayed. While celastrol treatment
did not significantly affect the climbing activity of wild
type control flies or DJ-1A RNAi flies rescued by hDJ-1, it
significantly improved the climbing activity of the DJ-1A
RNAi flies (Fig. 7A), even though the activity was not fully
restored to wild type level.
We also tested the effects of celastrol in a genomic dele-
tion mutant of DJ-1A, DJ-1A(Δ72). In this mutant, the
entire DJ-1A locus and some surrounding sequence were
deleted [21]. Both wild type control flies and DJ-1A(Δ72)
flies were raised under either celastrol-fed or yeast-fed
conditions. After 20 days of treatment, the animals were
subjected to H2O2 treatment. We found that while celas-
trol treatment did not affect the survival rate of wild type
control flies under H2O2-induced oxidative stress, it con-
ferred moderate but statistically significant improvement
on the survival of DJ-1A(Δ72) flies (Fig. 7B). Together,
HPLC analysis of the effects of celastrol and minocycline  treatments on brain dopamine content Figure 4
HPLC analysis of the effects of celastrol and minocy-
cline treatments on brain dopamine content. Head 
homogenates of 10-day-old Ddc-Gal4>DJ-1A RNAi flies 
treated with celastrol or minocycline were measured for 
dopamine content by HPLC. These were compared with 
untreated Ddc-Gal4>DJ-1A RNAi flies and control Ddc-Gal4/+ 
flies with or without drug treatments. Results are the mean ± 
SD of 21 homogenized heads for each genotype and drug 
treatment. *: P < 0.05 and **: P < 0.01 in ANOVA with Dun-
nett's post test.
HPLC analysis of the effects of NBQX and coQ10 treat- ments on brain dopamine concentration Figure 5
HPLC analysis of the effects of NBQX and coQ10 
treatments on brain dopamine concentration. Head 
homogenates of 10-day-old Ddc-Gal4>DJ-1A RNAi flies 
treated with NBQX or coQ10 were measured for dopamine 
content by HPLC. These were compared with untreated 
Ddc-Gal4>DJ-1A RNAi flies. Control Ddc-Gal4/+ flies with or 
without drug treatment were similarly analyzed. Results are 
represented as mean ± SD of 21 homogenized heads for 
each genotype and drug treatment. *: P < 0.05 in ANOVA 
with Dunnett's post test. Note that there appears to be a sig-
nificant variation in dopamine level between untreated con-
trol and DJ-1 RNAi flies used in this experiment and those 
used in Fig. 4. This could be due to slight variations in animal 
age, which can have a strong effect on brain dopamine level 
[20], or due to sensitivity of dopamine stability to variations 
in each experimental condition.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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these results support that celastrol treatment could amel-
iorate various cellular deficits associated with DJ-1A inac-
tivation.
Discussion
Loss-of-function mutations in the DJ-1 gene have been
associated with inherited forms of PD. Although familial
forms of PD are rare, studies of their gene products can
provide valuable insights into the pathogenic mecha-
nisms underlying idiopathic PD. The isolation of familial
PD genes has helped to create animal models of the dis-
ease, which can be used for pharmacological testing. In
the present study, the neuroprotective effects of four
drugs, celastrol, minocycline, coQ10 and NBQX, were
studied in a Drosophila DJ-1 model of PD. The parameters
used here, brain dopamine level and the survival of DNs
within the DMC, are relevant to the pathological hall-
marks seen in PD patients. The results shown here there-
fore have implications for the introduction of new
neuroprotective drugs into clinical practice as well as for
further understanding the role of DJ-1 in normal
dopaminergic physiology and PD pathogenesis.
Compounds combining antioxidant and anti-inflammatory 
properties provide neuroprotection in a fly DJ-1A model of 
PD: celastrol and minocycline studies
As described earlier, neuronal degeneration in PD is
accompanied by oxidative damage and inflammation.
Oxidative damage, one likely source of which being the
metabolites of dopamine, manifests itself through mito-
chondrial dysfunction and elevated levels of metals and
neuromelanin [66]. Inflammation in PD is presumably
mediated by activated microglia and their release of
inflammatory cytokines [67,70], as well as nitric oxide
[71,74]. A drug with both antioxidant and anti-inflamma-
tory activities is thus expected to effectively mitigate neu-
ronal degeneration in PD. Minocycline and celastrol both
exhibit this salient combination of dual properties. In
accordance with their comparable profiles of action, sim-
ilar effects on DN number and brain dopamine levels
were observed with these two drugs in our study. Both
drugs were able to halt the loss of DNs and replenish
dopamine content to near normal levels in DJ-1A RNAi
flies. Minocycline and celastrol were previously shown to
protect against MPTP-induced neurotoxicity in mice PD
models [75,76], although divergent results exist [77].
Drug studies in toxin-induced models of a disease, how-
ever, always bear a confounding effect of the drug reacting
directly with the toxin. Thus, a seemingly neuroprotective
effect of a drug might be conferred by chemical reaction of
the drug with the toxin that results in attenuated toxicity.
Here we show in an independent genetic model of PD
that the neuroprotective potential of the two drugs is not
restricted to pharmacologically induced models. To fur-
ther increase the likelihood of the drugs' efficacy in idio-
pathic cases, it might be interesting to test these two drugs
in other PD models, which may operate through different
pathogenic mechanisms.
Our results suggest that both minocycline and celastrol
may prove effective in preventing and/or delaying the pro-
gression of PD. However, comparable results were
achieved at very different doses, indicating different
potency of the two drugs. To produce the same neuropro-
tective effect as celastrol, minocycline needs to be applied
at a more than 10,000-fold higher concentration. This
Immunohistochemical analysis of TH+ DA neurons in the  DMC to show the effects of various drug treatments Figure 6
Immunohistochemical analysis of TH+ DA neurons in 
the DMC to show the effects of various drug treat-
ments. Frontal paraffin sections of adult fly brain were 
stained with anti-TH antibody. Representative sections con-
taining DA neurons in the DMC were shown for each geno-
type. 25-day-old female flies were analyzed. A-F: Ddc-
Gal4>DJ-1A RNAi flies. A: yeast fed no-drug control, B: 20 μg/
ml celastrol-treated, C: 50 mg/ml minocycline-treated, D: 5 
μg/ml celastrol + 25 mg/ml minocycline-treated, E: 30 mg/ml 
NBQX-treated, F: 100 mg/ml coQ10-treated. G, H: Ddc-
Gal4/+ flies. G: yeast fed no-drug control, H: 30 mg/ml 
NBQX-treated.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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information is relevant especially when the development
of protective or preventive medicine is concerned. After
all, an augmentation of the drug concentration required
to reach the desired therapeutic effect is generally accom-
panied by an increase of unwanted side effects. Neuropro-
tective therapy requires the long-term administration of
the drug to symptomatic but not yet end-stage patients. In
the MPTP mouse model of PD, an oral minocycline con-
centration of 120 mg/kg day was required to produce a
protective effect [75]. The high dose of minocycline given
to animals, which is significantly more than what is typi-
cally given to humans, is a potential problem. The dose
we found to be effective in the fly (50 mg/ml) is also rela-
tively high. Lower doses were tried in our dosing studies
but were found to be ineffective (data not shown).
Minocycline has been used for many years as an antibiotic
and is considered relatively safe. However, the recom-
mended dose of minocycline is 100 mg to 200 mg/day
[78]. High doses of minocycline antibiotics display the
same side effects of tetracycline antibiotics. Furthermore,
minocycline has a tendency to accumulate in various tis-
sues [79]. Thus, a high dose regimen over longer periods
of time might not be recommended. Studies using mino-
cycline should therefore be cautiously evaluated before
being used as a basis for human trials. Minocycline has
already been incorporated into a clinical investigation by
the NINDS/NIH, in which it is administered in the dose
of 100 mg in combination with 5g creatine (twice daily)
to otherwise untreated PD patients. It remains to be seen
the neuroprotective effect of minocycline in a drug-com-
bination regimen. Our results do suggest that a derivative
drug with similar antioxidant and anti-inflammatory
effects as minocycline but fewer side effects might deserve
serious consideration as a PD therapeutic.
Celastrol shows more promising potential as a candidate
to be further tested in preclinical PD models. Celastrol has
been described previously as having potent antioxidant
and anti-inflammatory properties in models of rheuma-
toid arthritis (RA), Crohn's disease, and Alzheimer's dis-
ease (AD) [33,80,81]. Here it is shown that the
administration of celastrol in low nanomolar doses pro-
vided excellent neuroprotection in a fly model of PD. The
effects observed with celastrol were similar to those
obtained with minocycline. However, celastrol must be
considered superior to minocycline with regard to toler-
ance in humans. Celastrol has a centuries-long history of
use in traditional Chinese medicine. In the present study,
celastrol exhibited approximately 10,000-fold higher neu-
roprotective potency than minocycline. At nanomolar
doses (7 μg/kgxd), celastrol was shown to improve learn-
ing and memory in a mouse AD model. Higher doses (3
mg/kgxd) were administered to mice, e.g. the MPTP
model of PD, without any observable side effects
[33,76,80]. Celastrol thus represents a potentially neuro-
Effects of celastrol treatment on the climbing activity of DJ-1A RNAi flies and oxidative stress sensitivity of DJ-1A genomic dele- tion flies Figure 7
Effects of celastrol treatment on the climbing activity of DJ-1A RNAi flies and oxidative stress sensitivity of DJ-
1A genomic deletion flies. A: Ddc-Gal4>UAS-DJ-1A RNAi flies, Ddc-Gal4>UAS-DJ-1A RNAi + hDJ-1 flies, and control wild type 
flies were treated with 20 μg/ml celastrol or mock-treated for 20 days before they were subjected to the climbing activity 
assay, in which the flies were bumped to the bottom of a plastic vial and the percentage of flies climbing to the top half of the 
vial after 7 seconds was quantified. Asterisks indicate P < 0.05 in Student's t-test. B: DJ-1A genomic deletion flies (Δ72) and con-
trol wild type (w-) flies were treated with 20 μg/ml celastrol or mock-treated for 20 days before they were subjected to the 
oxidative stress assay, in which the flies were exposed to 0.5% H2O2 and the survival rate over a 100 hour period was quanti-
fied. Asterisks indicate P < 0.05 in Student's t-test.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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protective treatment for PD, as it targets at least two main
pathogenic factors. It could be administered as single
treatment early in the course of the disease and later in
combination with L-DOPA or dopamine agonists, where
it might be effective at reduced doses. Since celastrol is
readily available and comparatively inexpensive, its use
may also bear economical benefits by delaying the admin-
istration of the more costly symptomatic medications.
The biogenic amine coQ10 fails to show effect in the DJ-1A 
RNAi model of PD
The reduction in complex I in the mitochondrial electron
transport chain in PD patients prompted the therapeutic
use of coQ10, the electron acceptor for mitochondrial
complex I. CoQ10 itself also has antioxidant properties.
Administration of coQ10 to the MPTP mouse model (200
mg/kgxd) and monkey model (15-22 mg/kgxd) attenu-
ated the neurotoxic effects of low dose MPTP [43,46]. Dif-
ferent from these previous studies, our present results do
not suggest obvious neuroprotective effects of coQ10 in
the DJ-1A RNAi model in the assays we performed. There
are several possible explanations for its lack of efficacy in
the fly model: 1) Due to its high molecular weight and
hydrophobicity, bioavailability of coQ10 is low in
humans [82,84], which might also be the case in the fly.
CoQ10 might not be stable in yeast paste or could be
metabolized rapidly before diffusing into brain tissue. 2)
The administered dose of 100 mg/ml might not have been
enough. 3) CoQ10 may be inefficacious in the DJ-1A
RNAi model of PD simply due to its unique mechanism
of action. Previous animal tests of coQ10 were done in
MPTP models of PD. MPTP acts through inhibition of
complex I of the mitochondrial respiratory chain, and
coQ10 is the very electron acceptor of complex I. Based on
these, one could assume that the therapeutic efficacy of
coQ10 might be restricted to the MPTP or other models
with electron transport deficits. However, electron trans-
port dysfunction might not be a primary effect of DJ-1
pathogenesis.
CoQ10 has already been implemented into clinical trials
on humans, but the results are inconclusive so far [85,90].
These studies differ significantly in their chosen outcome
measures. Some of them are in patients with early disease
not yet requiring medication, others in patients with
advanced disease already requiring medication, which
might not be suitable for neuroprotective trials. Based on
our findings, one could extrapolate that if coQ10 did con-
fer neuroprotective effects in humans, it would be limited
to specific patient populations.
NBQX has differential effects on DN number and 
dopamine levels in DJ-1A RNAi flies
After it was realized that excitotoxicity conferred by excess
glutamate in the basal ganglia circuit contributes to neu-
ronal degeneration in PD [52], AMPA-selective glutamate
receptor (GluR) antagonists have been pursued as poten-
tial neuroprotective agents. The use of the AMPA receptor
antagonist NBQX in the fly DJ-1A RNAi model yielded
divergent results with regards to DN preservation and the
attenuation of neurotransmitter depletion. NBQX admin-
istration conferred excellent protection against DJ-1A
RNAi-induced DN degeneration. However, it had little
effect on dopamine level reduction. This divergence might
be explained, if dopamine depletion occurs before neuro-
nal degeneration. NBQX might have successfully pro-
tected against secondary glutamate-induced excitotoxicity
and the subsequent DN cell death, but not reduction of
dopamine levels, for which other mechanisms than exci-
totoxicity might be responsible. It is not clear how DJ-1A
dysfunction affects brain dopamine levels. The dopamine
biosynthetic enzyme TH clearly is still present in DNs of
DJ-1A RNAi animals, since it is detected by immunostain-
ing, although its level appears to be reduced in these neu-
rons. Its activity could also be reduced in DJ-1A mutant
condition. These findings thus could be consistent with a
hypothetical course of events, in which dopamine deple-
tion precedes DN death. Our results also suggest that exci-
totoxicity does make certain contribution to neuronal
death in PD, but it is clearly not the primary cause. They
also argue that simply blocking DN degeneration may not
always lead to accompanying restoration of brain DA level
and dopaminergic function.
Interestingly, NBXQ treatment (30 mg/ml) appears to be
toxic for Ddc-Gal4/+  control flies. Reduced neuronal
number and decreased dopamine levels were observed.
Furthermore, it was noted that NBQX-fed wild type flies
exhibited pre-mature mortality and markedly reduced life
span (data not shown). In contrast, NBQX-fed DJ-1A
RNAi flies did not display any life span reduction, nor did
the flies of either genotype treated with any of the other
drugs used in this study. It is not clear how NBQX confers
toxicity to wild type flies but not the DJ-1A RNAi flies. It
is possible that the toxicity is conferred by its competitive
mechanism of action. In the control flies with normal
glutamate concentrations, AMPA inhibition might reduce
the intrinsic activity of glutamatergic neurotransmission
to an extent that is incompatible with life, leading to neu-
ronal death by lack of physiological stimulation. In the
DJ-1A RNAi fly with presumed excess excitatory glutama-
tergic activity, competitive inhibition might lead to near
normal level of glutamate action. Despite NBQX's recep-
tor selectivity and potency in animal models, it has to be
eliminated as a drug candidate for human use because of
its poor pharmacokinetics. Its low water solubility at
physiological pH, combined with a fast renal excretion,
cause crystallization in the kidney at therapeutic doses.
The fast excretion also prevents any prolonged systemic
activity in humans following oral administration [50].
Therefore newer compounds with better pharmacokinetic
properties are being actively pursued [91,93].BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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Implications for PD therapy
This study presents an in vivo system for testing candidate
neuroprotective drugs for PD. None of the drugs discussed
above would provide a cure for PD. Some of them, how-
ever, appear to be able to delay or decelerate disease pro-
gression by directly influencing established pathogenic
factors. The ability to directly interfere with disease pro-
gression would constitute a major improvement to cur-
rent symptomatic treatments of PD. Preventive/protective
medication would be more efficacious when applied
early. In the DJ-1A fly model, treatment was offered as
early as the beginning of adulthood (day 1). Of the four
drugs tested in this study, celastrol may bear the greatest
neuroprotective potential for use in idiopathic PD, taking
into account its neuroprotective effect and its side-effect
profile. The findings of this study appear to favour the
hypothesis that oxidative stress may represent an early
pathogenic event underlying PD. Oxidative stress is
thought to arise from the metabolism of dopamine itself,
which produces DOPA-quinones through auto-oxidative
processes and leads to the accumulation of neuromelanin
and iron, eventually causing mitochondrial dysfunction
[66]. All other players theorized to precipitate PD, like
protein aggregation, defects in the ubiquitin proteasome
system, inflammation, and excitotoxicity, can easily be
considered as consequences of oxidative damage. In turn,
a cycle of degenerative events ensues through the genera-
tion of secondary oxidative stress (Fig. 8). Of the second-
ary disease-propagating factors, inflammation may have
greater and faster destructive potential. Logically, suppres-
sion of this prime executor of injury and death, in addi-
tion to the primary insult, namely oxidative stress, would
confer an effective delay of the neurodegenerative
progress. The present results with minocycline and celas-
trol in the fly DJ-1A model strongly corroborate this
hypothesis.
Drosophila: a valuable model for pre-clinical 
pharmacological studies
The findings of this study support the suitability of Dro-
sophila for pre-clinical pharmacological studies. Drosophila
possesses a complex nervous system of approximately
300,000 neurons, composed of numerous specialized
subtypes that utilize major classes of neurotransmitters,
receptors, ion channels and signaling pathways found in
humans. The complexity of the Drosophila brain enables
learning and memory and other higher cognitive func-
tions. Moreover, Drosophila exhibits numerous sophisti-
cated behaviours, whose impairment can be related to
neural pathologies in the disease models [94]. All of these
qualities could be employed to qualify and quantify the
effects of neuroactive drugs in Drosophila. Because of its
short lifespan and high reproduction rate, Drosophila
would be valuable for first-step drug screens. Only those
drugs that show promise in Drosophila might be moved on
to mammals, resulting in faster and more economical ani-
mal testing.
To date, a number of studies have been carried out in
which flies respond to drugs added to their food. Drug
feeding to flies has been described for reserpine and sev-
eral biogenic amines, such as octopamine, L-DOPA,
dopamine, tyramine, tyrosine, 3, 5-diiodotyrosine
[95,97]. In the Drosophila α-Synuclein model of PD, oral
administration of the Hsp90 inhibitor Geldanamycin was
shown to have efficacy [59]. Earlier studies in Drosophila
Huntington's disease models showed that feeding of his-
tone deacetylase inhibitors (either alone or in combina-
tion with congo red and cysteine) arrested progressive
neuronal degeneration [98,99]. Volatile drugs such as
cocaine, alcohol, and nicotine have been administered in
aerosols to Drosophila  and elicited biological responses
[100,103].
Our present study further supports Drosophila as a useful
tool for pre-clinical drug testing for neurodegenerative
diseases. Staining of DMC DNs and direct dopamine
measurement represent easily measurable and reliable
methods for drug screenings in Drosophila. In addition,
the administration of drug preparations in yeast paste was
accepted by the fly and validated as a feasible approach.
Ingestion of drugs could be easily monitored, since most
drugs bear chromophores that can be detected in the
digestive system through the fly's semi-transparent cuticle
and also in their faeces. Clearly, experimental procedures
could be improved and refined. For example, dose finding
in the present study was based on previous empirical val-
ues. It might be helpful in the future to measure the effec-
tive concentrations of at least a certain number of drug
prototypes within the fly's brain tissue after oral adminis-
tration. This will generate conversion factors, which will
facilitate dose estimation in future studies
Conclusion
Drosophila genetic models of PD offer great potential for
elucidating disease mechanisms because of their amena-
bility to systematic genetic analysis, including genetic
screens for novel players in the disease process. Our
results presented here support that Drosophila  genetic
models of PD are also excellent tools for testing the thera-
peutic potential of drugs. Our analysis showed that mino-
cycline and celastrol, two compounds with antioxidant
and anti-inflammatory properties, are effective in attenu-
ating the loss of DNs and reduction of brain dopamine
levels in a Drosophila  DJ-1A model of PD. This result
emphasizes oxidative stress and inflammation in DJ-1
pathogenesis. Further testing of minocycline and celastrol
in other fly PD models will test the generality of the
involvement of oxidative stress and inflammation in
inducing the neuropathology observed in these diseaseBMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
Page 13 of 17
(page number not for citation purposes)
models. Second generation compounds based on modifi-
cation of minocycline or celastrol could offer effective
drugs for PD intervention. High throughput compound
screening with the fly PD models could also facilitate the
discovery of novel PD therapeutics.
Methods
Drosophila Genetics and Molecular Biology
Adult Drosophila of the genotypes Ddc-Gal4>DJ-1A RNAi,
Ddc-Gal4>DJ-1A RNAi + hDJ-1, and Ddc-Gal4/+ were used
in most experiments. The Ddc-Gal4 line and the w- wild
type stock were obtained from the Bloomington Dro-
sophila  Stock Center. Genomic DNA/cDNA constructs
were generated to create UAS-DJ-1A RNAi transgenics, as
described earlier [104]. Analysis of the UAS-DJ-1A RNAi
and UAS-hDJ-1  transgenes was performed as described
[20,58].
Animals and Drug Feeding
Drugs, dissolved in 10% DSMO, were mixed into wet
yeast paste. Drug-containing yeast paste was offered
together with standard fly food in standard vials housing
approximately 10 flies each. All drug preparations were
mixed freshly every 2-3 days. Flies were administered
celastrol (1 μg/ml, 5 μg/ml, and 20 μg/ml), minocycline
(25 mg/ml, 50 mg/ml), NBQX (30 mg/ml), coenzyme
Q10 (100 mg/ml), or yeast paste containing 10% DMSO
alone as non-treatment control. Drug feeding was carried
out at 25°C for 25 days from day 1 after eclosion. Approx-
imately 21-24 flies for each drug and genotype were proc-
essed for HPLC-based dopamine measurement after 10
days of treatment. 10-25 fly heads per group were evalu-
ated by immunohistochemistry after 25 days of treatment.
Therapeutic doses were based on dose-finding studies,
which compared known oral doses in mammals based on
weight, metabolic rate etc. and through parallels to sub-
stances previously administered to the fly
[95,97,100,103].
Histology and Immunohistochemistry
For counting DN number with the peroxidase/DAB
method, the heads of 1-day and 25-day old adult flies
were dissected, formaldehyde-fixed and paraffin embed-
A diagram depicting possible pathogenic events in PD Figure 8
A diagram depicting possible pathogenic events in PD. A hypothetical series of molecular events likely contributing to 
PD pathogenesis is diagrammed. Potential sites of action by the neuroprotective agents used in this study are indicated.BMC Neuroscience 2009, 10:109 http://www.biomedcentral.com/1471-2202/10/109
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ded as previously described [58]. Serial 10 μm frontal sec-
tions were cut from anterior to posterior to include the
entire brain. Anti-TH polyclonal antibody (1:100, Pel
Freez Biologicals) served as primary antibody. Incubation
was carried out over night at 4°C. For subsequent process-
ing, the Vectastain Universal Elite ABC Kit (Vector Labora-
tories) was used. Immunopositive cells of the
dorsomedial cluster at the level of the giant interneuron
commissure were counted throughout all sections, using
a light microscope (Nikon Eclipse 3000, Japan). Similar
methods have been used previously to analyze dopamin-
ergic degeneration in various Drosophila  models of PD
[20,57,59]. For counting DN number with whole-mount
confocal microscopy of TH immunostaining, the proce-
dure was carried out essentially as described [64].
HPLC Measurement of Dopamine
For sample preparation, 10-day-old female fly heads were
dissected out under mild CO2 anaesthesia, and quickly
homogenized in chilled 0.1 M perchloric acid using a
motorized, hand-held tissue homogenizer. 3 heads were
used per 50 μl perchloric acid sample. Homogenates were
frozen immediately on dry ice and stored at -80 degrees
prior to HPLC measurement. 21-24 fly heads were meas-
ured per genotype and per experiment.
For measurement of dopamine, a modified HPLC proto-
col for catecholamine measurement was used as described
earlier [76,105]. The chilled homogenates of fly heads
were centrifuged and 10 μl of supernatant fluid was eluted
through an 80 × 4.6 mm C18 column (ESA Inc, Chelms-
ford, MA, USA). The mobile phase contained 75 mM of
NaH2PO4, 1.5 mM Octanesulfonic acid (OSA), 5% Ace-
tonitrile (pH 3.0). For coulometric electrochemical detec-
tion, a two-channel Coulochem II electrochemical
detector (ESA, Inc) was used. The flow rate was 1 ml/min.
Concentrations of DA were expressed as nanograms per
milliliter (ng/ml).
Climbing Activity and Oxidative Stress Assays
To measure climbing activity, we transferred into empty
plastic vials 12 to 20 female flies that have been treated or
mock-treated with 20 μg/ml celastrol for 20 days and
counted the number of flies climbing up to the top quar-
ter of the vial within a 7-second period, after being
bumped to the bottom of vertically standing vials, as pre-
viously described [64]. We repeated each measurement as
indicated using three independent fly cohorts per geno-
type. For oxidative stress treatment, cohorts of female flies
(n = 20-30 each) treated or mock-treated with 20 μg/ml
celastrol for 20 days after eclosion were transferred to
plastic vials containing a tissue paper socked with 0.5%
H2O2 prepared in Schneider's insect medium. At least
three independent vials were set up for each genotype and
drug treatment condition. The survival rate was measured
as previously described [20].
Data Analysis
All data were analyzed using Microsoft Excel and Graph
Pad InStat3 software.
The effects of minocycline, celastrol, NBQX and coQ10
ingestion on neuronal survival within the DMC of sec-
tioned or whole-mount fly brains were analyzed with a
one-way analysis of variance (ANOVA). Multiple pair-
wise comparisons of the means were performed using
Dunnett's Multiple Comparison Tests: The effects of the
respective drugs on dopamine concentration within the
fly head were also analyzed with a one-way analysis of var-
iance (ANOVA) and the Dunnett's Multiple Comparison
as post-test. Student's t-test was used when a single pair of
data was compared. Differences for all data were consid-
ered statistically significant at P < 0.05. For both studies,
mean numbers of surviving neurons or dopamine con-
tent, respectively, were plotted as columns. Error bars
indicate the standard deviation of the mean (SD).
Number of asterisk indicates statistical significance. ***, P
< 0.0001; ** P < 0.01; * P < 0.05; no asterisk, P > 0.05.
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